January 4, 2013

Building a Coral Reef against Type 2 Diabetes


endobarrierIt sounds like somewhat of a fairy-tale but it’s as real as a heart attack. Medtronic and GlaxoSmithKline are teaming up with GI Dynamics, addressing the global epidemic of Type 2 diabetes. The plan is to understand how EndoBarrier affects glucose levels and obesity in people with Type 2 diabetes.

Like a barrier reef, EndoBarrier is a thin, flexible, tube-shaped liner that forms a barrier between food and a part of the intestinal wall. It is placed using an endoscope and does not require invasive surgery.  In clinical trials, EndoBarrier has been shown to achieve rapid reductions in blood sugar levels and weight loss of approximately 20% in 12 months.

Learn more about the EndoBarrier.  Click on the video featuring Dr. Sorli. He’s intense – as anybody would be on the ground of this “paradigm shift” in Type 2 diabetes. The YouTube video shows the device and how it is implanted. Apparently Medtronic and GlaxoSmithKline have caught the EndoBarrier enthusiasm, as seen in the worldwide reaction from doctors and patients.

Although it has yet to be approved in the United States, Europe and Australia have been using it for over a year in treating Type 2 diabetes. EndoBarrier is entering a pivotal clinical trial in the United States and is currently commercially available in select countries in Europe, including Germany, Austria, the United Kingdom and the Netherlands, as well as Australia and Chile.

The collaboration of GlaxosmithKlein and Medtronic  is a joint venture to understand two things, specifically. How does EndoBarrier impact continuous glucose levels (Medtronic) and evaluating hormonal changes in response to EndoBarrier Therapy (GSK) to further characterize the mechanism of action. With that better understood, it may be game over in the global war against obesity and Type 2 diabetes.